Siegfried (SIX: SFZN), a global Contract Development and Manufacturing Organization (CDMO), announced the appointment of Eduardo Montanha as Chief Operating Officer and member of the Executive Committee, effective September 1, 2026. The move follows Siegfried's decision to combine the Chief Operating Officer roles for Drug Substances and Drug Products into a single position, aligning with the company's strategy to offer integrated end-to-end solutions across the pharmaceutical value chain.
Montanha brings more than 20 years of international leadership experience in pharmaceutical and biopharmaceutical manufacturing. He most recently served as Executive Vice President, Head of Global Technical Operations & Quality at Fresenius Kabi, where he led an integrated global network of approximately 30 manufacturing sites across multiple regions. Earlier in his career, he held senior leadership roles at Takeda, Sandoz, Hexal, and Hoechst/Aventis, covering technical operations, quality, supply, and large-scale manufacturing networks.
In his new role, Montanha will focus on further strengthening supply performance, operational efficiency, and reliability across Siegfried's global network. His strong track record in integrated operations is expected to enhance the company's ability to serve its pharmaceutical clients with seamless solutions from drug substances to drug products.
Marcel Imwinkelried, Chief Executive Officer of Siegfried, stated: "I am very pleased to welcome Eduardo to Siegfried. He brings outstanding global operations and quality leadership experience and will play an important role in further enhancing supply performance, operational efficiency and reliability for our customers."
Montanha holds a bachelor's degree in chemical engineering, a postgraduate qualification in Industrial Automation, and an MBA in Project Management. He has extensive international leadership experience, having lived and worked across Europe and Latin America.
The appointment comes as Siegfried continues to grow its global footprint. The company operates 16 sites in Switzerland, Germany, Spain, France, Malta, the USA, Australia, and China. In 2025, Siegfried reported sales of CHF 1,327.8 million and employed more than 3,800 people. Siegfried Holding AG is publicly listed on the SIX Swiss Exchange (SIX: SFZN).
For business leaders, this leadership change signals Siegfried's commitment to operational excellence and integrated service delivery, which could improve reliability and speed for pharmaceutical clients seeking a single partner for both active pharmaceutical ingredients (APIs) and drug products. The consolidation of COO roles may also lead to more streamlined decision-making and cost efficiencies, potentially benefiting the broader pharmaceutical supply chain.
More details are available in the original announcement on NewMediaWire.
